Literature DB >> 11208568

Angiotensin-(1--7) in the ovine fetus.

K M Moritz1, D J Campbell, E M Wintour.   

Abstract

In the adult animal, ANG-(1-7) may counterbalance some effects of ANG II. Its effects in the fetus are unknown. Basal ANG-(1-7), ANG I, ANG II, and renin concentrations were measured in plasma from ovine fetuses and their mothers (n = 10) at 111 days of gestation. In the fetus, concentrations of ANG I, ANG-(1-7), and ANG II were 86 +/- 21, 13 +/- 2, and 14 +/- 2 fmol/ml, respectively. In the ewe, concentrations of ANG I were significantly lower (20 +/- 4 fmol/ml, P < 0.05) as were concentrations of ANG-(1-7) (2.9 +/- 0.6 fmol/ml), whereas ANG II concentrations were not different (10 +/- 1 fmol/ml). Plasma renin concentrations were higher in the fetus (4.8 +/- 1.1 pmol ANG I x ml(-1) x h(-1)) than in the ewe (0.9 +/- 0.2 pmol x ml(-1) x h(-1), P < 0.05). Infusion of ANG-(1-7) (approximately 9 microg/h) for a 3-day period caused a significant increase in plasma concentrations of ANG-(1-7) reaching a maximum of 448 +/- 146 fmol/ml on day 3 of infusion. Plasma levels of ANG I and II as well as renin were unchanged by the infusion. Urine flow rate, glomerular filtration rate, and fetal arterial blood pressure did not change and were not different than values in fetuses receiving a saline infusion for 3 days (n = 5). However, the osmolality of amniotic and allantoic fluid was significantly higher in fetuses that received ANG-(1-7). Also, compared with the saline-infused animals, mRNA expression levels of renin, the AT(1) receptor, and AT(2) receptor were elevated in kidneys of fetuses that received infusions of ANG-(1-7). Infusion of an ANG-(1-7) antagonist ([D-Ala(7)]-ANG-(1-7), 20 microg/h) for 3 days had no effect on fetal blood pressure or renal function. In conclusion, although infusion of ANG-(1-7) did not affect fetal urine flow rate, glomerular filtration rate, or blood pressure, changes in fetal fluids and gene expression indicate that ANG-(1-7) may play a role in the fetal kidney.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11208568     DOI: 10.1152/ajpregu.2001.280.2.R404

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  7 in total

1.  Reduced systolic pressure load decreases cell-cycle activity in the fetal sheep heart.

Authors:  P F O'Tierney; D F Anderson; J J Faber; S Louey; K L Thornburg; G D Giraud
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-05-19       Impact factor: 3.619

2.  Exaggerated sympathetic mediated responses to behavioral or pharmacological challenges following antenatal betamethasone exposure.

Authors:  Hossam A Shaltout; Mark C Chappell; James C Rose; Debra I Diz
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-03-08       Impact factor: 4.310

Review 3.  Development of fetal brain renin-angiotensin system and hypertension programmed in fetal origins.

Authors:  Caiping Mao; Lijun Shi; Feichao Xu; Lubo Zhang; Zhice Xu
Journal:  Prog Neurobiol       Date:  2009-01-24       Impact factor: 11.685

4.  Administration of D-Alanine-[Ang-(1-7)] (A-779) Prior to Pregnancy in Sprague Dawley Rats Produces Antidiuresis in Late Gestation.

Authors:  J Joyner; Laa Neves; Cm Ferrario; Kb Brosnihan
Journal:  J Am Soc Hypertens       Date:  2008

5.  The ACE2/Ang-(1-7)/Mas Axis Regulates the Development of Pancreatic Endocrine Cells in Mouse Embryos.

Authors:  Lin Wang; Juan Liang; Po Sing Leung
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

6.  Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis.

Authors:  Jiandong Zhang; Nancy A Noble; Wayne A Border; Yufeng Huang
Journal:  Am J Physiol Renal Physiol       Date:  2009-12-23

Review 7.  Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy.

Authors:  Christoph Schindler; Peter Bramlage; Wilhelm Kirch; Carlos M Ferrario
Journal:  Vasc Health Risk Manag       Date:  2007
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.